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Abstract
Wolfram syndrome (WS), also known as DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness), is a rare auto-
somal recessive syndrome (1/770,000 in the United Kingdom), characterised by juvenile onset of diabetes mellitus, optic nerve atrophy, 
diabetes insipidus, sensorineural deafness, renal tract and neurological abnormalities, and primary gonadal atrophy. WS is caused mainly 
by biallelic mutations in the WFS1 gene, which encodes wolframin. Wide tissue distribution of wolframin and many mutations in the 
wolframin gene resulting in Wolfram syndrome may contribute to different phenotypes and the unusual combinations of clinical features. 
We describe a female patient with Wolfram syndrome diagnosed at the age of 25, with a previous false diagnosis of type 1 diabetes mellitus 
and misdiagnosed diabetic complications. The patient was found to be a compound heterozygote for two novel mutations in exon 8 of WFS1 
gene: a 2-bp deletion AT at nt 1539 leading to a frameshift (Y513fs) and a single-base substitution 1174C > T resulting in a stop codon (Q392X). 
A detailed analysis of the patient’s medical history and a review of the literature suggest that many cases of Wolfram syndrome may 
remain undiagnosed due to misdiagnosis as type 1 diabetes mellitus and incorrect interpretation of clinical symptoms of neurodegenera-
tive abnormalities, especially in their early stages. (Endokrynol Pol 2014; 65 (5): 398–400)
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Streszczenie
Zespół Wolframa (WS), znany również jako DIDMOAD (moczówka prosta, cukrzyca, atrofia nerwu wzrokowego i głuchota), jest rzadkim 
zespołem dziedziczonym autosomalnie recesywnie (1/770000 w Wielkiej Brytanii), charakteryzującym się wystąpieniem cukrzycy w wieku 
młodzieńczym, zanikiem nerwu wzrokowego, moczówką prostą, głuchotą, niewydolnością oddechową i zaburzeniami neurologicznymi 
oraz pierwotną atrofią gonad. WS jest spowodowany głównie mutacją w genie WFS1, który koduje wolframinę. Obecność wolframiny 
w wielu tkankach organizmu oraz wiele różnych mutacji w genie wolframiny, których skutkiem jest wystąpienie zespołu Wolframa, może 
stanowić przyczynę różnych fenotypów tego zespołu oraz różnych kombinacji cech klinicznych. 
W poniższej publikacji opisano przypadek pacjentki z zespołem Wolframa, której choroba początkowo była błędnie zdiagnozowana jako 
cukrzyca typu 1 i jej powikłania. W badaniach genetycznych wykazano, że pacjentka była heterozygotą w zakresie dwóch nowych mu-
tacji w egzonie 8 genu WFS1: 2-bp delecji AT w regionie nt 1539, prowadzącej do mutacji zmiany ramki odczytu (Y513fs) oraz substytucji 
pojedynczej zasady 1174 C > T, czego skutkiem był stop kodon (Q392X). 
Ze szczegółowej analizy historii medycznej pacjentki oraz przeglądu piśmiennictwa wynika, że duża liczba przypadków zespołu Wol-
frama może zostać niewłaściwie rozpoznana jako cukrzyca typu 1 lub zaburzenia neurodegeneracyjne, zwłaszcza w początkowej fazie 
ich rozwoju. (Endokrynol Pol 2014; 65 (5): 398–400)
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Background
Wolfram syndrome (WS), described for the first time in 
1938 and also known as DIDMOAD (Diabetes Insipidus, 
Diabetes Mellitus, Optic Atrophy and Deafness), is 
a rare autosomal recessive syndrome characterised 
mainly by the association of early-onset insulin-
dependent diabetes mellitus and optic atrophy [1, 2]. 
Diabetes mellitus, as well as progressive, bilateral optic 
atrophy occur before the age of 15. Other clinical fea-
tures of WS are diabetes insipidus, multiple neurological 
abnormalities, such as sensorineural deafness, neuro-
pathic bladder, cerebellar ataxia, dysarthria, dysphagia, 
startle myoclonus, reduced limb reflexes, horizontal 
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nystagmus, central apnoeas, loss of taste and smell, 
hemiparesis, mental retardation, psychiatric illness, and 
renal tract abnormalities [1, 3, 4]. Symptoms of WS may 
include primary gonadal atrophy and reduced fertility 
[1]. Patients usually die at the median age of 30 (range 
25–49 years) as a result of brainstem atrophy or renal 
failure secondary to infections [1, 3]. The prevalence of 
the syndrome is 1/770,000 in the United Kingdom [1]. 
WS is caused mainly by biallelic mutations in the 
WFS1 gene, which encodes wolframin, located in 
chromosome 4p16.1 and consisting of 8 exons [5, 6]. 
Wolframin plays a role in the biosynthesis of protein, 
regulation of charged calcium ions homeostasis in the 
ER, and is involved in the regulation of ER stress [7, 8]. 
To date, about 130 mutations of the WFS1 gene result-
ing in Wolfram syndrome have been reported [9, 10]. 
Case report
A 25-year-old female patient with a previous diagnosis of 
type 1 diabetes mellitus complicated by blindness related 
to retinopathy, with nephropathy and neuropathy as well, 
gave birth to her first child (first pregnancy, first labour, 
caesarean section) in the 38th week of pregnancy. A few 
days after the labour, the patient was admitted to the De-
partment of Diabetology because of high glycaemia levels. 
The laboratory results were as follows: glycated 
haemoglobin (HbA1C) - 52 mmol/mol (6.8%), mor-
phology, ionogram, serum creatinine and glomeru-
lar filtration rate (GFR), albumin concentration in 
urine sample and gasometry within normal ranges, 
C-peptide — 0.068 ng/mL (normal range: 1.1–4.4). 
On the first day, the glycaemia levels ranged from 
80 to 240 mg/dL. Afterwards, during further hospi-
talisation, fasting glycaemia levels were: 79–221 mg/dL, 
postprandial glycaemia: 97–250 mg/dL. The patient was 
treated with insulin administered intravenously for the 
first 20 hours of hospitalisation (0.5–3 IU/h), then subcu-
taneously: before meals and NPH in the morning and 
before bedtime (total insulin dose: 0.5 IU/kg/24 hours). 
Despite significant glycaemic improvement 
and almost normal serum glucose levels, polyuria 
(6.7–8.2 litres per 24 hours) was observed, accompa-
nied by a low specific gravity of the urine (1.010). In 
fundoscopic examination, no signs of retinopathy were 
found, but bilateral optic atrophy was diagnosed and 
confirmed through FVER (visually evoked response) 
examination. No sign of peripheral neuropathy was 
found in a detailed clinical assessment. All these find-
ings and clinical features pointed to Wolfram syndrome 
with the presence of diabetes insipidus. The patient was 
given desmopressin (0.5 mg p.o. per 24 hours), which re-
sulted in a decreased diuresis: 2–3 litres per 24 hours, and 
higher specific gravity of urine: 1.020. That confirmed the 
diagnosis of diabetes insipidus. The patient did not com-
plain of any problems with hearing; no pathologies were 
found during the otoscopic examination. Audiometry 
showed bilateral high frequency (more than 1,500 Hz) 
sensorineural hearing loss. An ultrasonography of the 
abdominal cavity was performed, showing a slight dila-
tion of the pyelocalyceal systems on both sides. 
In this paragraph, we present the patient`s past 
medical history. She was diagnosed with diabetes at the 
age of seven and insulin treatment was introduced at 
diagnosis, with the following doses: 0.7–1.0 IU/kg, with 
varying glycaemic control (HbA1c in the past in the range 
55–70 mmol/mol [7.2–8.6%]) and no episodes of ketoaci-
dosis. At the age of 15, reduced visual acuity occurred and 
progressed gradually. Fundoscopic examination was per-
formed several times as the deterioration of the subject`s 
vision progressed, and no features of diabetic retinopathy 
were observed. At the age of 17, the ophthalmologist de-
scribed bilateral optic atrophy for the first time, together 
with divergent squint and nystagmus. The patient`s visual 
fields at that time showed peripheral constriction. When 
blindness occurred at the age of 20, the ophthalmologist 
attributed it to bilateral maculopathy. 
The patient had been complaining of polyuria for 
many years. However, glucose levels during that time 
were rather low, and it was regarded by the patient 
as a symptom of diabetes mellitus. Low urine specific 
gravity was observed a number of times.
Since the diagnosis of diabetes mellitus, sonography 
of the abdomen was performed several times and pel-
vicalyceal dilatation was always found in both kidneys. 
Dilated renal outflow tracts were diagnosed early, when 
the patient was about seven years old. A few months 
before the current hospitalisation, the patient was 
hospitalised in the urology ward due to pyelonephritis 
with bilateral hydronephros Io and voiding difficulty. 
In the patient`s family, the grandfather (the patient`s 
mother`s father) suffered from type 2 diabetes.
A detailed analysis of the medical history pointed 
to WS and a false diagnosis of type 1 diabetes mellitus 
and its complications. 
A genetic test was performed in the patient and in 
some members of her family. The gene analysed was 
WFS1. The patient was found to be a compound het-
erozygote for two novel mutations in exon 8: a 2-bp de-
letion AT at nt 1539 leading to a frameshift (Y513fs) and 
single-base substitution 1174C > T resulting in a stop 
codon (Q392X). The patient`s mother was heterozygous 
for Q392X and her father was heterozygous for Y513fs. 
The subject`s younger sister was found to be a carrier 
of Y513fs and her older sister a homozygous wild type. 
At present, the patient undergoes regular examina-
tions at diabetes outpatient clinic, her condition is good 
and stable, and the desmopressin treatment is continuing. 
400
False diagnosis of type 1 diabetes mellitus and its complications in Wolfram syndrome Katarzyna Homa et al.
O
PI
S 
PR
ZY
PA
D
K
U
Discussion
The typical sequence of the occurrence of the patholo-
gies in patients with Wolfram syndrome is: diabetes 
mellitus in the first decade of life, optic atrophy in the 
first or early in the second decade, diabetes insipidus 
and sensorineural hearing loss in the second decade, 
dilated renal outflow tracts early in the third decade and 
neurological abnormalities early in the fourth decade 
of life [11, 12]. 
In our study, the patient`s age at diagnosis of 
diabetes mellitus was typical for Wolfram syndrome 
(seven years). The clinical course of diabetes was also 
characteristic, with low insulin requirement, fairly good 
metabolic control, and no episodes of ketoacidosis. 
The first symptoms of optic atrophy also occurred at a 
usual age, when the patient was about 15. Our patient 
demonstrated typical symptoms: reduced visual acu-
ity with progressive sight deterioration, no features of 
diabetic retinopathy, peripheral constriction of visual 
fields, fundoscopic signs of optic nerve atrophy. All 
these symptoms, together with the lack of retinopathy, 
are usually reported in Wolfram syndrome patients [13]. 
The symptoms of diabetes insipidus were present in 
our patient already in her childhood, which is also typi-
cal for this abnormality in WS patients. The diagnosis 
of a sensorineural hearing defect was established at 
25 years of age and based on audiometry, with no previ-
ous complaints of hearing problems from the patient. 
What was not typical was the very early (the patient 
was aged seven) appearance of urodynamic disorders. 
Usually, Wolfram syndrome patients present renal 
tract disorders, with urinary frequency, incontinence 
and recurrent infections, at the median age of 20 years 
(10–44 years) [3]. In our patient, there was no problem 
with conception and no complications occurred dur-
ing pregnancy. Despite the fact that primary gonadal 
atrophy and reduced fertility occur in a number of 
patients suffering from Wolfram syndrome, successful 
pregnancies ending with the birth of healthy children 
have been reported as well [1]. Wide tissue distribution 
of wolframin and many mutations in the wolframin 
gene resulting in Wolfram syndrome may contribute 
to different phenotypes and atypical sequences of 
clinical features. 
Although all the symptoms occurred in our pa-
tient quite early, the proper diagnosis of WS was 
established late — at the age of 25. The false diagnosis 
of type 1 diabetes and mistaking the typical features 
of Wolfram syndrome as diabetic complications may 
result in the very rare incidence of WS and a low 
vigilance of medical staff toward this syndrome. As-
suming that the prevalence of Wolfram syndrome in 
young people with diabetes in Europe is 1/730, as was 
reported recently in a multicentre study, the number 
of subjects diagnosed with this syndrome should be 
much higher than that given in the literature [14]. 
Genetic studies of WS performed in different Euro-
pean countries usually have included relatively small 
numbers of patients — 41 in the UK [15], 22 in Spain 
[16], and six in Poland [17]. 
Conclusions
Although Wolfram syndrome is rare, it should be con-
sidered in a case of the presence of diabetes mellitus 
accompanied by symptoms of progressive optic atrophy 
and hearing loss, diabetes insipidus or renal tract dis-
orders. Some of the cases diagnosed as type 1 diabetes 
mellitus are in fact subjects with Wolfram syndrome. 
Genetic tests should be performed in all patients in 
whom there is a suspected presence of Wolfram syn-
drome, as well as among their family members. 
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